Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...

Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Senior Advocate Diya Kapur, representing the petitioner, informed the court that some gyms were promoting these drugs as a ...

Pharma giants are sweating on the results of a federal government request for guidance on adding weight loss drugs to the ...